Emergent BioSolutions (EBS) said Monday it has agreed to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million.
The facility includes manufacturing, laboratory, warehouse, and office space, the company said. It expects to close the sale in Q1.
Emergent will retain the rights to secure manufacturing services and capacity at the facility in partnership with Syngene as part of the deal, Emergent said.
Price: 5.73, Change: -0.04, Percent Change: -0.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.